• T Ruhstaller, L Widmer, J C Schuller, A Roth, V Hess, W Mingrone, R von Moos, M Borner, B C Pestalozzi, S BalmerMajno, D Köberle, L Terraciano, A Schnider, S Bodis, R Popescu, and Swiss Group for Clinical Cancer Research (SAKK).
• Department of Oncology and Hematology, Kantonsspital, St Gallen, St Gallen. Electronic address: thomas.ruhstaller@kssg.ch.
• Ann. Oncol. 2009 Sep 1; 20 (9): 1522-1528.

BackgroundThis multicenter phase II study investigated the efficacy and feasibility of preoperative induction chemotherapy followed by chemoradiation and surgery in patients with esophageal carcinoma.Patients And MethodsPatients with locally advanced resectable squamous cell carcinoma or adenocarcinoma of the esophagus received induction chemotherapy with cisplatin 75 mg/m(2) and docetaxel (Taxotere) 75 mg/m(2) on days 1 and 22, followed by radiotherapy of 45 Gy (25 x 1.8 Gy) and concurrent chemotherapy comprising cisplatin 25 mg/m(2) and docetaxel 20 mg/m(2) weekly for 5 weeks, followed by surgery.ResultsSixty-six patients were enrolled at eleven centers and 57 underwent surgery. R0 resection was achieved in 52 patients. Fifteen patients showed complete, 16 patients nearly complete and 26 patients poor pathological remission. Median overall survival was 36.5 months and median event-free survival was 22.8 months. Squamous cell carcinoma and good pathologically documented response were associated with longer survival. Eighty-two percent of all included patients completed neoadjuvant therapy and survived for 30 days after surgery. Dysphagia and mucositis grade 3/4 were infrequent (<9%) during chemoradiation. Five patients (9%) died due to surgical complications.ConclusionsThis neoadjuvant, taxane-containing regimen was efficacious and feasible in patients with locally advanced esophageal cancer in a multicenter, community-based setting and represents a suitable backbone for further investigation.

27 keywords...

hide…